MedPac proposes changes to Part B

In its annual report to Congress, the Medicare Payment Advisory Commission proposed changes to reimbursement for Medicare Part B drugs, including setting a flat fee for infused drugs as well as value-based models.

Under Part B, physicians are reimbursed average sales price (ASP) plus 6%. MedPac said the system could give physicians incentives to prescribe higher-priced drugs when equally effective, less expensive alternatives exist. ...